The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer

Despite the use of front-line anticancer drugs such as paclitaxel for ovarian cancer treatment, mortality rates have remained almost unchanged for the past three decades and the majority of patients will develop recurrent chemoresistant disease which remains largely untreatable. Overcoming chemoresi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bates, Mark, Spillane, Cathy D., Gallagher, Michael F., McCann, Amanda, Martin, Cara, Blackshields, Gordon, Keegan, Helen, Gubbins, Luke, Brooks, Robert, Brooks, Doug, Selemidis, Stavros, O’Toole, Sharon, O’Leary, John J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769460/
https://www.ncbi.nlm.nih.gov/pubmed/33370338
http://dx.doi.org/10.1371/journal.pone.0243715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769460/
https://www.ncbi.nlm.nih.gov/pubmed/33370338
http://dx.doi.org/10.1371/journal.pone.0243715

Ejemplares similares